Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 277
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT03525574 | A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy | ||
| NCT06508762 | A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-993 | ||
| NCT00262483 | Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C | ||
| NCT01554085 | First in Human Study of ALS-002158; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1 | ||
| NCT04702360 | ELX/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients With at Least One F508del Mutation | ||
| NCT01685801 | Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR Function | ||
| NCT01060566 | Study of VX-770 on Midazolam and Rosiglitazone and the Effect of Fluconazole on VX-770 | ||
| NCT00933283 | A Study to Investigate the Potential Interaction Between Telaprevir and Methadone, at Steady-State | ||
| NCT03125395 | A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation | ||
| NCT02669849 | Study to Assess the Efficacy and Safety of VX-210 in Subjects With Acute Traumatic Cervical Spinal Cord Injury | ||
| NCT03691779 | Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age | ||
| NCT07283770 | Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants | ||
| NCT05111145 | A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF) | ||
| NCT03206749 | A Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy | ||
| NCT02565914 | A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation | ||
| NCT07010406 | A Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacicept Presentations | ||
| NCT01821963 | Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC) | ||
| NCT05865171 | A Study to Evaluate Pharmacokinetics (PK) and Safety of Inaxaplin in Participants With Renal Impairment | ||
| NCT00758043 | A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response | ||
| NCT00420784 | A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3) | ||
| NCT03163511 | A Safety, Tolerability, and Efficacy Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness | ||
| NCT03447249 | A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF) | ||
| NCT05033080 | A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF) | ||
| NCT02875366 | A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR Mutation | ||
| NCT05951205 | Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/βC Genotype | ||
| NCT00591214 | Safety and PK Study of MP-424 to Treat Chronic Hepatitis C | ||
| NCT00457821 | Safety Study of Ivacaftor in Subjects With Cystic Fibrosis | ||
| NCT00627926 | A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV) | ||
| NCT03525444 | A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF) | ||
| NCT05541471 | A Study to Evaluate the Pharmacokinetic Drug-drug Interactions Between VX-548, Midazolam, and Digoxin | ||
| NCT03227471 | A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis | ||
| NCT01701063 | An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus | ||
| NCT01048255 | Study of VX-765 in Subjects With Treatment-resistant Partial Epilepsy | ||
| NCT01161537 | Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis and the G551D Mutation | ||
| NCT02823470 | A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor/Ivacaftor Adherence in CF Subjects Homozygous for the F508del CFTR Mutation | ||
| NCT00205465 | Phase 2 Clinical Study in Psoriasis With Oral Investigational Drug VX-765 | ||
| NCT07161037 | Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW) | ||
| NCT00395577 | A Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702 | ||
| NCT01790100 | A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C | ||
| NCT03150719 | A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in Orkambi® (Lumacaftor/Ivacaftor) -Experienced Subjects With Cystic Fibrosis (CF) | ||
| NCT00923728 | A Phase I Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors | ||
| NCT02392234 | A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation | ||
| NCT00088504 | Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C | ||
| NCT00780416 | Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C | ||
| NCT05518734 | A Phase 1 Dose Escalation Study of VX-708 in Healthy Participants | ||
| NCT00500812 | A Safety Study for Cethrin (BA-210) in the Treatment of Acute Thoracic and Cervical Spinal Cord Injuries | ||
| NCT00865904 | Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene Mutation | ||
| NCT03068312 | A Study to Evaluate Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Have a 3849 + 10KB C→T or D1152H CFTR Mutation | ||
| NCT04599465 | A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF) | ||
| NCT05661734 | A Single-arm Study to Evaluate Safety and Effectiveness of VX-548 for Acute Pain |
